Biomedical Occupation or Discipline

Odyssey Therapeutics Appoints Dennis Dean as EVP, Head of Non-Clinical Development

15 hours ago talkbio0Tagged Autoimmune Diseases, Biological Factors, Dennis Dean, Drug Development, executive vice president, Head of Non-Clinical Development, Odyssey Therapeutics, preclinical research

Odyssey Therapeutics; Dennis Dean; Executive Vice President; Head of Non-Clinical Development; preclinical research; autoimmune diseases; drug development; biopharmaceutical

Voyager Therapeutics Partners with Transition Bio for Small Molecule Neurodegenerative Drug Discovery; CRISPR Therapeutics Ends Work on CAR-T Therapy

1 day ago talkbio0Tagged Amyotrophic Lateral Sclerosis, CAR-T therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Development, Neurodegenerative Disorders, Partnership, Pick Disease of the Brain, small molecule drug discovery, TARDBP gene, Transition Bio, Voyager Therapeutics

Voyager Therapeutics; Transition Bio; ALS; frontotemporal dementia; TDP-43; small molecule drug discovery; neurodegenerative diseases; CRISPR Therapeutics; CAR-T therapy; partnership; drug development

Spotlight On: What to Watch at AHA 2025 – Key Science and Trends

2 days ago talkbio0Tagged 2025, Autoimmune hemolytic anemia, Cardiology discipline, cardiometabolic, Cardiopulmonary Resuscitation, Clinical Trials, coronary trials, gene editing therapies, Guidelines, Hypertensive disease, Interventional procedure, lipid management, Medical Valves, polypill, Science

AHA 2025; late-breaking science; clinical trials; cardiology; gene-editing therapies; polypill; lipid management; valve and coronary trials; cardiometabolic intervention; hypertension; CPR guidelines

Eli Lilly Strikes Multiple Deals for Ultra-Rare Eye Disease Gene Therapy and RNAi Partnerships

2 days ago talkbio0Tagged AAV-AIPL4, eli lilly, gene therapy, Genetic Leap, Leber congenital amaurosis-4, MeiraGTx, Ophthalmology specialty, partnerships, RNA Interference, SanegeneBio

Eli Lilly; MeiraGTx; gene therapy; Leber congenital amaurosis-4; AAV-AIPL4; Genetic Leap; RNAi; SanegeneBio; ophthalmology; biotech partnerships

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Highlighting Integration of Clinical Innovation, Multi-Omics, and AI for Solid Tumor Therapies

1 week ago talkbio0Tagged Artificial Intelligence, CAN-2409, Candel Therapeutics, enLIGHTEN Discovery Platform, Immunotherapy, Malignant neoplasm of prostate, Multiomics, Non-Small Cell Lung Carcinoma, Precision Medicine, SITC, Solid Neoplasm

Candel Therapeutics; SITC 2025; immunotherapy; CAN-2409; multi-omics; artificial intelligence; solid tumors; enLIGHTEN Discovery Platform; prostate cancer; non-small cell lung cancer; precision medicine

Dr. Andreas Wallnöfer Named to Optigo Biotherapeutics Board of Directors

1 week ago talkbio0Tagged Andreas Wallnöfer, Biotechnology, board of directors, Dosage Forms, Drug Development, Hyaluronic Acid anchoring platform, IND-enabling studies, Ophthalmology specialty, Optigo Biotherapeutics, R&D, Retinal Diseases

Andreas Wallnöfer; Optigo Biotherapeutics; Board of Directors; ophthalmology; biotechnology; retinal diseases; IND-enabling studies; Hyaluronic Acid anchoring platform; pharmaceutical R&D; drug development

M42 and Oracle Join Forces to Advance Healthy Longevity and Disease Prevention

1 week ago talkbio0Tagged disease prevention, electronic health record - ActClassContainer, Emirati Genome Program, healthy longevity, Oracle Health, personalized healthcare, Pharmacogenomics, Precision Medicine, UAE

M42; Oracle Health; healthy longevity; disease prevention; precision medicine; Emirati Genome Program; pharmacogenomics; electronic health record (EHR); personalized healthcare; UAE

Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors

1 week ago talkbio0Tagged Aging, Biotechnology, board of directors, cellular rejuvenation, David Guyer, Drug Development, epigenetic reprogramming, ER-100, Life Biosciences

Life Biosciences; David Guyer; Board of Directors; biotechnology; cellular rejuvenation; epigenetic reprogramming; ER-100; aging; drug development

Otsuka Acquires Asia-Pacific Rights to 4D Molecular Therapeutics’ Retinal Gene Therapy 4D-150 for $85 Million

2 weeks ago talkbio0Tagged 4D Molecular Therapeutics ', Asia-Pacific, gene therapy, Macular edema due to diabetes mellitus, Ophthalmology specialty, Otsuka, strategic partnership, Wet Age-Related Macular Degeneration

Otsuka; 4D Molecular Therapeutics; 4D-150; Asia-Pacific rights; gene therapy; wet age-related macular degeneration; diabetic macular edema; $85 million; strategic partnership; ophthalmology

Lilly Commits $1.2 Billion to Expand GLP-1 Pill Manufacturing Facility in Puerto Rico

2 weeks ago talkbio0Tagged Carolina, eli lilly, expansion, Investments, Manufacturing, Oral Medicine, orforglipron, pharmaceutical production, Product containing glucagon-like peptide 1 receptor agonist (product), Puerto Rico, supply chain, United States

Eli Lilly; Puerto Rico; GLP-1 receptor agonist; orforglipron; manufacturing expansion; oral medicines; investment; Carolina; pharmaceutical production; U.S. supply chain